Back to Search
Start Over
Efficacy of immunological antivirus therapy for papillomavirus-associated grade I cervical intraepithelial neoplasia
- Source :
- V.F.Snegirev Archives of Obstetrics and Gynecology. 8:155-166
- Publication Year :
- 2021
- Publisher :
- ECO-Vector LLC, 2021.
-
Abstract
- AIM: The study aimed to assess the effectiveness of alloferon in human papillomavirus (HPV)-associated cervical neoplasia (grade I) based on the analysis of the cytokine profile in cervical mucus as well as markers of apoptosis in cervical epithelial cells. MATERIALS AND METHODS: The study enrolled 98 women, including 55 women of reproductive age with cervical intraepithelial neoplasia (CIN) associated with HPV infection and 43 conditionally healthy women without HPV infection. Factors of cytokine response and markers of apoptosis under normal and pathology conditions were assessed and compared. RESULTS: The imbalance of pro-inflammatory and anti-inflammatory cytokines, in favor of the latter, is an important factor that supports the persistence of HPV-associated grade I CIN. Reducing caspase-3 and caspase-9, increasing interleukin-18, and subsequent activation of interferon gamma against the background of alloferon use are favorable signs of substantial elimination of the HPV. CONCLUSIONS: The results of this study show considerable elimination of HPV in patients with grade I CIN when using immunological antivirus therapy.
- Subjects :
- Oncology
Cervical cancer
medicine.medical_specialty
business.industry
HPV infection
virus diseases
Cervical intraepithelial neoplasia
medicine.disease
female genital diseases and pregnancy complications
Apoptosis
Internal medicine
Medicine
Interleukin 18
Interferon gamma
Human papillomavirus
business
Genotyping
medicine.drug
Subjects
Details
- ISSN :
- 26871386 and 23138726
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- V.F.Snegirev Archives of Obstetrics and Gynecology
- Accession number :
- edsair.doi...........0c58412b08105d4c2cedd414fee142bf
- Full Text :
- https://doi.org/10.17816/2313-8726-2021-8-3-155-166